Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In March 2010, as part of Affordable Care Act, Congress passed a well-conceived and critical legislative bill, the Biologic Pricing and Competition Innovation Act of 2009 (BPCIA)i. Despite its intentions, BPCIA has been instituted so that it complicates prescribing while increasing health care costs and reducing competition, rather than resulting in the anticipated benefits.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Distinguished Professor of Medicine; Associate director for clinical research and director, GI Oncology; Rutgers Cancer Institute; Director of oncology research, RWJBarnabas Health
Executive director, Oncology Pharmacy Services & Research Shared Resource, Rutgers Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Distinguished Professor of Medicine; Associate director for clinical research and director, GI Oncology; Rutgers Cancer Institute; Director of oncology research, RWJBarnabas Health
Executive director, Oncology Pharmacy Services & Research Shared Resource, Rutgers Cancer Institute

Login